Literature DB >> 24959463

Study of Changes in Renal Function by Perindopril and Telmisartan during Treatment of Systemic Hypertension.

Manish Kumar1, Lalit Mohan2, Harihar Dikshit3.   

Abstract

BACKGROUND: Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARBs) has been a major therapeutic advance in the management of hypertensive patients. This study was designed to compare adverse effects on renal markers in treatment with two commonly used drugs Perindopril and Telmisartan in cases of Hypertension. This was an 'observational' and 'cross-sectional' study.
METHODS: This study was conducted in two groups, Group A (Newly diagnosed hypertensive patients) and Group B (Old but poorly controlled hypertensive), each had 100 patients. In both groups, half the patients were given Perindopril 4 mg OD and half were given Telmisartan 40 mg OD for 24 weeks. If blood pressure was not controlled, dose was titrated to response and increased to 8 mg OD and 80 mg OD for Perindopril and Telmisartan respectively to keep mean arterial pressure between 90-115 mmHg. The adjusted dose was kept constant in both groups. Blood urea, serum creatinine and creatinine clearance was estimated initially and then at 4(th), 12(th) and 24(th) week.
RESULTS: Treatment with Perindopril showed that mean baseline values for blood urea, serum creatinine and creatinine clearance in newly diagnosed and old hypertensive patients were 30.88, 1.37, 64.09 and 33.68, 1.53, 55.98, respectively. After study period these values were 32.24, 1.40, 63.97 and 29.80, 1.46, 59.23 respectively (p value > 0.05). Treatment with telmisartan showed that mean baseline values of blood urea, serum creatinine and creatinine clearance in both group of patients were 30.88, 1.52, 59.31, and 31.72, 1.40, 65.67, respectively. After treatment these values in both groups were 31.92, 1.43, 62.66; and 32.20, 1.46, 61.70, respectively (p value > 0.05).
CONCLUSION: It concluded that both Perindopril and Telmisartan significantly reduces systolic, diastolic and mean arterial pressure without any significant effect on renal function in both newly diagnosed and old hypertensive patients.

Entities:  

Keywords:  Blood urea; Hypertension; Perindopril; Serum creatinine and Creatinine clearance; Telmisartan

Year:  2014        PMID: 24959463      PMCID: PMC4064922          DOI: 10.7860/JCDR/2014/8012.4275

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  11 in total

Review 1.  Essential hypertension. Part I: definition and etiology.

Authors:  O A Carretero; S Oparil
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

2.  Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

Authors:  B E Karlberg; L E Lins; K Hermansson
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

3.  Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.

Authors:  R Kuperstein; Z Sasson
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

4.  A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.

Authors:  S Bavanandan; Z Morad; O Ismail; A Chandran; T Thayaparan; M Singaraveloo
Journal:  Med J Malaysia       Date:  2005-06

5.  Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients.

Authors:  J H Chen; J J Cheng; C Y Chen; H C Chiou; T Y Huang; C D Tsai; M M Y Fu; W J Cherng
Journal:  Int J Clin Pract Suppl       Date:  2004-12

6.  The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group.

Authors:  J M Flack; C Yunis; J Preisser; C B Holmes; G Mensah; B McLean; E Saunders
Journal:  Arch Intern Med       Date:  2000-06-26

7.  A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group.

Authors:  M G Myers
Journal:  Can J Cardiol       Date:  1996-11       Impact factor: 5.223

8.  Blood pressure as a cardiovascular risk factor: prevention and treatment.

Authors:  W B Kannel
Journal:  JAMA       Date:  1996 May 22-29       Impact factor: 56.272

9.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

10.  The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.

Authors:  J Sennesael; A Ali; P Sweny; M Vandenburg; D Slovic; M Dratwa; G Resplandy; P Genissel; P Desche
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

View more
  2 in total

1.  Association of Left Ventricular Hypertrophy With a Faster Rate of Renal Function Decline in Elderly Patients With Non-End-Stage Renal Disease.

Authors:  Hong-tao Shi; Xiao-jing Wang; Jun Li; Gui-fang Song; Zhe-yong Huang; Xiang-yu Guo; Jun-jie Guo; Zhi-yang Lv; Hong-wei Li; Jun-bo Ge; Jie Cui; Guan-ming Qi
Journal:  J Am Heart Assoc       Date:  2015-11-09       Impact factor: 5.501

2.  Simultaneous determination of indapamide, perindopril and perindoprilat in human plasma or whole blood by UPLC-MS/MS and its pharmacokinetic application.

Authors:  Yi Tao; Sheng Wang; Lei Wang; Min Song; Taijun Hang
Journal:  J Pharm Anal       Date:  2018-05-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.